Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;7(2):254-257.
doi: 10.1016/j.euf.2021.02.006. Epub 2021 Feb 27.

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Jones T Nauseef  1 , Neil H Bander  1 , Scott T Tagawa  2
Affiliations
Review

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Jones T Nauseef et al. Eur Urol Focus. 2021 Mar.

Abstract

Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond 177Lu-PSMA-617, which is covered elsewhere. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer tumors and on limited other areas in the body. It can be targeted to treat prostate cancer using radioactive particles, drugs, or immune agents.

Keywords: Bispecific antibodies; Monoclonal antibodies; Prostate cancer; Prostate-specific membrane antigen; Radionuclide; Targeted radionuclide therapy.

PubMed Disclaimer

Publication types